Current innovations in mRNA vaccines for targeting multidrug-resistant ESKAPE pathogens DOI Creative Commons
Saber İmani,

S. Lv,

Hongbo Qian

и другие.

Biotechnology Advances, Год журнала: 2024, Номер unknown, С. 108492 - 108492

Опубликована: Дек. 1, 2024

The prevalence of multidrug-resistant (MDR) ESKAPE pathogens, including Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, and Pseudomonas aeruginosa, represents a critical global public health challenge. In response, mRNA vaccines offer an adaptable scalable platform for immunotherapy against pathogens by encoding specific antigens that stimulate B-cell-driven antibody production CD8

Язык: Английский

Transmission Dynamics and Novel Treatments of High Risk Carbapenem-Resistant Klebsiella pneumoniae: The Lens of One Health DOI Creative Commons

Jiaying Zhu,

Taoyu Chen, Yanmin Ju

и другие.

Pharmaceuticals, Год журнала: 2024, Номер 17(9), С. 1206 - 1206

Опубликована: Сен. 12, 2024

The rise of antibiotic resistance and the dwindling antimicrobial pipeline have emerged as significant threats to public health. emergence carbapenem-resistant

Язык: Английский

Процитировано

9

Clinical and microbiological characteristics and prognosis of invasive infection caused by Klebsiella pneumoniae in the community DOI Creative Commons
Hongkui Sun, Hanlin Zhang, Zongfa Ruan

и другие.

Annals of Medicine, Год журнала: 2025, Номер 57(1)

Опубликована: Янв. 10, 2025

Background The incidence of invasive infection Klebsiella pneumoniae (Kp) in the community is increasing every year, and high disability mortality rates associated with them pose great challenges clinical practice. This study aimed to explore microbiological characteristics Kp community.

Язык: Английский

Процитировано

1

Genetically Engineered Bacterial Ghosts as Vaccine Candidates Against Klebsiella pneumoniae Infection DOI Creative Commons
S. V. Dentovskaya, A. S. Vagaiskaya, A. S. Trunyakova

и другие.

Vaccines, Год журнала: 2025, Номер 13(1), С. 59 - 59

Опубликована: Янв. 10, 2025

Background/Objectives Bacterial ghosts (BGs), non-living empty envelopes of bacteria, are produced either through genetic engineering or chemical treatment retaining the shape their parent cells. BGs considered vaccine candidates, promising delivery systems, and adjuvants. The practical use in development for humans is limited because concerns about preservation viable bacteria BGs. Methods: To increase efficiency Klebsiella pneumoniae BG formation and, accordingly, to ensure maximum killing we exploited previously designed plasmids with lysis gene E from bacteriophage φX174 holin–endolysin systems λ L-413C phages. Previously, this kit made it possible generate bacterial cells Yersinia pestis varying degrees hydrolysis variable protective activity. Results: In current study, showed that co-expression holin endolysin genes phage elicited more rapid efficient K. than mediated by only single low functioning system phage. introduction alternative lysing factors into instead protein leads loss murein skeleton. resulting frameless cell envelops reminiscent sacs skins Although such structures less naive classical ghosts, they provide effective protection against infection a hypervirulent strain can be recommended as candidate vaccines. For our generated using O1:K2 strain, both safety immunogenicity aspects were evaluated. Humoral cellular immune responses significantly increased mice intraperitoneally immunized compared subcutaneously vaccinated animals (p < 0.05). Conclusions: Therefore, study presents novel perspectives future research on ghost

Язык: Английский

Процитировано

0

Phages adapt to recognize an O-antigen polysaccharide site by mutating the ‘backup’ tail protein ORF59, enabling reinfection of phage-resistant Klebsiella pneumoniae DOI Creative Commons
Ping Li, Wenjie Ma, Jun Cheng

и другие.

Emerging Microbes & Infections, Год журнала: 2025, Номер unknown

Опубликована: Янв. 16, 2025

Phages demonstrate remarkable promise as antimicrobial agents against antibiotic-resistant bacteria. However, the emergence of phage-resistant strains poses challenges to their effective application. In this paper, we presented isolation a phage adaptive mutant that demonstrated enhanced and sustained antibacterial efficacy through co-evolution Klebsiella pneumoniae (K. pneumoniae) 111-2 ZX1Δint in vitro. Our experiments revealed successfully completed adsorption phase by binding host surface, specifically targeting capsular polysaccharide (CPS) receptor via primary receptor-binding protein (RBP) ORF60 auxiliary RBP ORF59. Upon exposure predation, mutations genes wbaP, wbaZ or wzc, which encode synthesis CPS, conferred resistance reducing adsorption. response these defense mechanisms, phages have evolved utilize an alternative site located on O-antigen lipopolysaccharide (LPS) mutation backup This evolutionary change enabled reinfect previously strains. Notably, PR2 carrying ORF59 Q777R, capacity infect both wild-type resistant strains, exhibiting prolonged activity wild conclusion, our findings elucidated complex phage-host adsorption-antagonism mechanism characterized mutation-driven alterations recognition. work contributes deeper understanding adaptability highlights potential for combat bacteria vitro approach.

Язык: Английский

Процитировано

0

Investigation on Klebsiella pneumoniae in the field of extracellular vesicles DOI Creative Commons
Jun Wu, Yuheng Liu, Jin Su

и другие.

Deleted Journal, Год журнала: 2025, Номер unknown

Опубликована: Март 13, 2025

Abstract Klebsiella pneumoniae (KP), recognized for its pronounced antibiotic resistance, is a prevalent agent of nosocomial infections such as hospital‐acquired pneumonia. The alarming rate serious and associated mortality renders KP significant public health threat. Extracellular vesicles (EVs) are pivotal in KP's physiological pathological mechanisms, facilitating material information transfer mediating interactions between the bacteria host. critical role EVs enhances our understanding pathophysiology, disease progression, strategies infection control. This review emphasizes mechanics resistance instrumental bacterium‐host interplay, proposing promising research focus advancing diagnosis, therapy, prevention.

Язык: Английский

Процитировано

0

Phage therapy for Klebsiella pneumoniae: Understanding bacteria–phage interactions for therapeutic innovations DOI Creative Commons
Julie Le Bris, Nathalie Chen,

Adeline Supandy

и другие.

PLoS Pathogens, Год журнала: 2025, Номер 21(4), С. e1012971 - e1012971

Опубликована: Апрель 8, 2025

Klebsiella pneumoniae (KP) is a Gram-negative bacterium that commonly resides in the human gastrointestinal tract and can also act as an opportunistic pathogen cause extra-intestinal infections. KP poses global health threat because it causes both hospital- community-acquired infections immune-competent immunocompromised hosts. These be multidrug-resistant and/or hypervirulent, making difficult to treat deadly. In absence of effective treatments for recalcitrant infections, bacteriophage (phage) therapy gaining attention promising alternative. this review, we evaluate epidemiology epitope diversity, discuss interactions between KP-targeting phages their bacterial hosts from eco-evolutionary perspective, summarize recent efforts phage treating We novel approaches, including genetic engineering machine learning, initial steps toward developing precision medicine approach emerging dangerous pathogen.

Язык: Английский

Процитировано

0

In-silico and experimental analysis of Klebsiella pneumoniae fimbriae subunits for vaccine development DOI
Lucas Assoni, Valéria Valim,

Ana Julia Melo Couto

и другие.

Vaccine, Год журнала: 2025, Номер 53, С. 127075 - 127075

Опубликована: Апрель 1, 2025

Язык: Английский

Процитировано

0

Comprehensive Analysis of Four Major Surface Proteins for Vaccine Design against Klebsiella pneumoniae DOI
Hamid Vaez,

Vahid Vaez

Infection Epidemiology and Microbiology, Год журнала: 2025, Номер 11(1), С. 1 - 12

Опубликована: Фев. 1, 2025

Язык: Английский

Процитировано

0

Computational strategies in Klebsiella pneumoniae vaccine design: navigating the landscape of in silico insights. DOI
Bruno Douradinha

Biotechnology Advances, Год журнала: 2024, Номер 76, С. 108437 - 108437

Опубликована: Авг. 30, 2024

Язык: Английский

Процитировано

3

Respiratory tract infections: an update on the complexity of bacterial diversity, therapeutic interventions and breakthroughs DOI

Avani Panickar,

Anand Manoharan, Anand Anbarasu

и другие.

Archives of Microbiology, Год журнала: 2024, Номер 206(9)

Опубликована: Авг. 17, 2024

Язык: Английский

Процитировано

1